Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 2Phase 4 1Phase 3 1Phase 2/3 1

Status

Completed 26Recruiting 9Active not recruiting 8Terminated 5Unknown 4Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1

Interventions

Capecitabine 25Oxaliplatin 24Paclitaxel 23Gemcitabine 21Cisplatin 21Fluorouracil 20Carboplatin 18Drug Therapy 17Docetaxel 17pembrolizumab 15Leucovorin 15Irinotecan 15Radiotherapy 12tislelizumab 11Injections 10Radiation 9Pemetrexed 9Magnetic Resonance Spectroscopy 9Bevacizumab 9toripalimab 8Cetuximab 8Surgical Procedures, Operative 7Specimen Handling 7Radiotherapy, Intensity-Modulated 7Azacitidine 7venetoclax 6sintilimab 6atezolizumab 6Topotecan 6Cyclophosphamide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Not yet recruiting × Everolimus × Clear all
NCT07407517 2026-02-12

POLARIS

Fudan University

Phase 3 Not yet recruiting
904 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡